Quality of life in chronic heart failure: Cilazapril and captopril versus placebo

Heart

Volumn 79, Issue 6, 1998, Pages 593-598

  Bulpitt, C J ^a,f   Fletcher, A E ^b   Dossegger L ^c   Neiss, A ^d   Nielsen, T ^c   Viergutz, S ^e  

^a Science and Technology   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

^e Gesell F Angew Math Informatik   (Germany)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ACE inhibitors; Captopril; Cilazapril; Congestive heart failure; Quality of life; Randomised controlled trial

Indexed keywords

CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; EXERCISE TEST; FATIGUE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PATIENT CODING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031839255     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.79.6.593     Document Type: Article

References (35)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure; results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
3. Yusuf S, for the SOLVD Investigators. Effect of enalapril on survival in patients with reduced ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. The Acute Infarction Ramapril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
5. Pfeffer MA, Braunwald E, Moyé LA, et al, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
6. Giles TD, Fisher MB, Rush JE. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor. Am J Med 1988;85(B):44-7.
7. Dössegger L, on behalf of the Cilazapril-Captopril Multicentre Group. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomised, multicentre trial. Cardiology 1995:86(suppl 1):34-40.
8. Larsen J, Sykulski R, Jensen G, et al. Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment. Comparison with long-term clinical effect. Eur J Clin Pharmacol 1996;50:433-11.
9. Sharpe DN, Douglas J, Coxon RJ, et al. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet 1980;ii:1154-7.
10. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels; nomenclature and criteria for diagnosis. 6th ed. Boston: Little Brown, 1964.
11. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
12. McNair DM, Lorr M, Doppleman LF. Manual for the profile of mood states. San Diego: Educational and Industrial testing Service, 1971.
13. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
14. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol 1990;30:353-64.
15. Bulpitt CJ, Fletcher AE. Measurement of the quality of life in congestive heart failure - influence of drug therapy. Cardiovasc Drug Ther 1988;2:419-24.
16. Wenger NK, Furberg CD. Cardiovascular disorders. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990:335-45.
17. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(suppl 3):S178-89.
18. Fletcher AE. Quality of life measurements in the evaluation of treatment: proposed guidelines. Br J Clin Pharmacol 1995;39:217-22.
19. Kubo SH, Gollub S, Bourge R, et al, for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992;85:942-9.
20. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response: effects of enalapril and placebo. Am J Cardiol 1989;64:50-5.
21. Baligadoo SJ, Subratty H, Manraz M, et al. Effects of enoximone on quality of life. Int J Cardiol 1990;28(suppl 1):S29-32.
22. Fletcher AE, McLoone P, Bulpitt CJ. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 1988;ii:4-8.
23. Blackwood R, Mayou RA, Garnham JC, et al. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther 1990;48:325-32.
24. Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments - cilazapril, atenolol, nifedipine. Hypertension 1992;19:499-507.
25. Rector TS, Kubo SH, Cohn JN. Patients' self assessment of their congestive heart failure: II content, reliability and validity of a new measure - the Minnesota living with heart failure questionnaire. Heart Failure 1987;3:198-209.
26. Lewis GRJ. Lisinopril versus placebo in older congestive heart failure patients. Am J Med 1988;85:4(suppl 3B):48-54.
27. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspneafatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989;64:50-5.
28. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64.
29. Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. J Hypertens 1992;10:1409-16.
30. Bosio A, Rosola R, Abbati C, et al. Antidepressant activity of angiotensin converting enzyme inhibitors. Current Therapeutic Research 1990;48:191-7.
31. Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. A comparison of captopril and enalapril. The Quality of Life Hypertension Study Group. N Engl J Med 1993;328:907-13.
32. The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. Arch Intern Med 1991;151:1413-23.
33. Fletcher A. Captopril, enalapril and quality of life [letter]. N Engl J Med 1993;329:505-6.
34. Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990;4: 217-25.
35. O'Brien AJ, Bulpitt CJ. The effects of ACE inhibitors on cognitive function. Drugs Aging 1995;6:173-80.